In a diversification bid, Charlotte, NC-based Carlisle Companies purchased Singapore's LHi Technology, a device industry supplier focused on cable manufacturing, for $195 million.
Tuesday, Valeant Pharmaceuticals said the FDA had served up a warning letter about its Sculptra Aesthetic manufacturing, citing problems it observed during a June 2014 inspection. The missteps from manufacturing standards might just fuel the fire from hostile buyout target Allergan.
Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.
Allergan may or may not bow to requests from some of its largest shareholders to wait on M&A until after December's special meeting. But in the meantime, it's continuing its barrage on predator Valeant's sales model, which it says will yield a tough Q4.
Just days after rumors emerged that AbbVie was looking for additional financing to cover its planned $55 billion takeover of Ireland's Shire, the company is going to great lengths to reassure employees that the deal is a go.
Astellas may not have wanted Ambit Biosciences as a development partner, but fellow Japanese pharma Daiichi Sankyo wants it as an acquisition.
The U.K.'s Horizon Discovery has snapped up St. Louis-based Sage Labs for $48 million in cash and stock.
Troubled KV Pharmaceuticals started a new life earlier this year, emerging from bankruptcy and changing its name to Lumara Health. Now, it's selling out. AMAG Pharmaceuticals agreed to pay up to $1.25 billion for the company's maternal health business and its once-controversial preterm-labor treatment Makena.
Valeant Pharmaceuticals isn't the only one who thinks Allergan should hold off on dealmaking till shareholders say their piece at a December special meeting. Three top-15 Allergan shareholders are urging the Botox maker to delay until investors weigh in on Valeant's hostile bid.
In light of new U.S. tax rules tightening the reins on corporate inversions, Medtronic could be poised to revise its $42.9 billion deal with Ireland-based Covidien.